Naptumomab estafenatox
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Naptumomab estafenatox
- DrugBank Accession Number
- DB12807
- Background
Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Naptumomab Estafenatox
- External IDs
- ABR-217620
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Naptumomab estafenatox. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Naptumomab estafenatox. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Naptumomab estafenatox. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab estafenatox. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Naptumomab estafenatox. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 93T929W6LC
- CAS number
- 676258-98-3
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911384
- Wikipedia
- Naptumomab_estafenatox
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2, 3 Completed Treatment Renal Cell Carcinoma (RCC) 1 1 Active Not Recruiting Treatment Bladder Cancer / Cervical Squamous Cell Carcinoma / Endometrial Cancer / Estrogen Receptor Positive Breast Cancer / Gastroesophageal Cancer (GC) / Hepatocellular Carcinoma / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Melanoma / Mesothelioma / Metastatic Colorectal Cancer (CRC) / Non-Small Cell Lung Cancer (NSCLC) / NSCL2 Gene Mutation / Ovarian Cancer / Pancreatic Adenocarcinoma / Prostate Cancer / Renal Cell Carcinoma (RCC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple-Negative Breast Cancer / Urothelial Cancer 1 1 Completed Treatment Non-Small Cell Lung Carcinoma 1 1 Completed Treatment Non-Small Cell Lung Carcinoma / Pancreatic Cancer / Renal Cell Carcinoma (RCC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 21, 2016 00:23 / Updated at February 24, 2021 23:07